ARGNF - argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call Transcript
argenx SE (ARGX) Q3 2021 Results Conference Call October 28, 2021 08:30 AM ET Company Participants Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Akash Tewari - Jefferies James Gordon - JP Morgan Danielle Brill - Raymond James Yatin Suneja - Guggenheim Joon Lee - Truist Tazeen Ahmad - Bank of America Rosie Turner - Barclays Jason Butler - JMP Securities Joel Beatty - Robert W. Baird Yanan Zhu - Wells Fargo Douglas Tsao - H. C. Wainwright Charles Pitman - Redburn Emmanuel Papadakis - Deutsche Bank Presentation Tim Van Hauwermeiren [Call Starts Abruptly] This might explain why patients consistently switch between treatments. Finally, there is a considerable market opportunity with approximately 16,000 to 17,000 addressable patients in the U.S. alone. We are continuing to enroll patients in the ADVANCE SUBCU, ADHERE, and ADDRESS trials for ITP, CIDP, and Vulgaris, respectively, which
For further details see:
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call Transcript